In a random selection of 62 critical covid patients, our drug outperformed the placebo at Day 14 by a factor of 82%. That is fact.
That data is useful to inform us for a future trial. That is the significance. That even if we cannot consider it as sufficient evidence for concluding efficacy (based on the anyhow inconclusive methods of chance) in the larger population, still we cannot deny that this data aligns congruently to the thesis that LL works for these patients. The data is suggesting the possibility of success and not the possibility of failure, and hence we are able to design the new trial based on it.
And we are presently doing that trial (hopefully). We will see what the results will bring. Proving in covid can have implications beyond covid since the MOA gets confirmed and that can find use elsewhere.
Market Data 
Markets 
